-+ 0.00%
-+ 0.00%
-+ 0.00%

REVOLUTION MEDICINES BEGINS TREATING PATIENTS IN PHASE 3 RASOLVE 308 TRIAL EVALUATING ZOLDONRASIB IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RAS G12D NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Reuters·10/20/2026 12:02:52